All In Biotech

Drug Trial Radar · NCT06548217

A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

An Open-label, Uncontrolled, Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Planned (sponsor's estimate)

Start

May 7, 2024

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid tumors. This study consists of the tolerability confirmation part to determine the recommended dose for Japanese participants by evaluating the DLTs and the expansion part to evaluate the safety and pharmacokinetics and to explore the efficacy.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • ONO-4538HSCDrug

    ONO-4538HSC will be administered subcutaneously once every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLT)Time frame: 28 days
  2. Adverse event (AE)Time frame: UP to 100 days after the last dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Niigata Cancer Center Hospital

    Niigata, Niigata, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, Japan

  • Kindai University Hospital

    Osakasayama-shi, Osaka, Japan

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital Of JFCR

    Koto-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.